Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 48 Records) |
| Query Trace: Neoplasms and CDA[original query] |
|---|
| Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenetics and genomics 2012 Feb 22 (2): 105-16. Li Liang, Schaid Daniel J, Fridley Brooke L, Kalari Krishna R, Jenkins Gregory D, Abo Ryan P, Batzler Anthony, Moon Irene, Pelleymounter Linda, Eckloff Bruce W, Wieben Eric D, Sun Zhifu, Yang Ping, Wang Liew |
| Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis. Hepato-gastroenterology 0 59 (117): 1609-13. Kasuya Kazuhiko, Tsuchida Akihiko, Nagakawa Yuichi, Suzuki Yoshiaki, Suzuki Minako, Aoki Tatsuya, Abe Yuta, Shimazu Motohide, Itoi Takao, Sofuni Atsus |
| Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Dec 6 (12): 2018-26. Ludovini Vienna, Floriani Irene, Pistola Lorenza, Minotti Vincenzo, Meacci Marialuisa, Chiari Rita, Garavaglia Daniela, Tofanetti Francesca Romana, Flacco Antonella, Siggillino Annamaria, Baldelli Elisa, Tonato Maurizio, Crinò Luc |
| Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2012 May 118 (9): 2466-75. Joerger Markus, Burgers Sjaak A, Baas Paul, Smit Egbert F, Haitjema Tjeerd J, Bard Martin P L, Doodeman Valerie D, Smits Paul H M, Vincent Andrew, Huitema Alwin D R, Beijnen Jos H, Schellens Jan H |
| Genetic polymorphisms of XPD and CDA and lung cancer risk. Oncology letters 2012 Aug 4 (2): 247-251. Zhou Min, Wan Huan-Ying, Gao Bei-Li, Ding Yong-Jie, Jun Rong-X |
| High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation. Clinica chimica acta; international journal of clinical chemistry 2012 Aug 413 (15-16): 1284-7. Xu Jialin, Zhou Yuhong, Zhang Jing, Chen Yuancheng, Zhuang Rongyuan, Liu Tianshu, Cai Weim |
| Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics 2013 Jul 14 (9): 1047-51. Serdjebi Cindy, Seitz Jean-François, Ciccolini Joseph, Duluc Muriel, Norguet Emmanuelle, Fina Frédéric, Lacarelle Bruno, Ouafik L'houcine, Dahan Laetit |
| Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. Genetics and molecular research : GMR 2014 13 (2): 3310-8. Zhou M, Ding Y J, Feng Y, Zhang Q R, Xiang Y, Wan H |
| The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis. The International journal of biological markers 0 29 (3): e224-32. Li Hui, Wang Xiangling, Wang Xiuw |
| Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget 2015 Mar 6 (8): 6422-30. García-González Xandra, Cortejoso Lucía, García María I, García-Alfonso Pilar, Robles Luis, Grávalos Cristina, González-Haba Eva, Marta Pellicer, Sanjurjo María, López-Fernández Luis |
| Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene 2015 Mar 559 (1): 31-7. Ding Xiangxiang, Chen Wenwei, Fan Haijian, Zhu B |
| The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer treatment reviews 2016 Nov 50 9-22. Lam S W, Guchelaar H J, Boven |
| Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. The pharmacogenomics journal 2016 Dec . Meulendijks D, Rozeman E A, Cats A, Sikorska K, Joerger M, Deenen M J, Beijnen J H, Schellens J H |
| Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. Pharmacological research 2017 Aug . Lam Siu W, van der Noort Vincent, van der Straaten Tahar, Honkoop Aafke H, Peters Godefridus J, Guchelaar Henk-Jan, Boven Ep |
| Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacological research 2017 Mar 120 133-137. Pellicer Marta, García-González Xandra, García María I, Robles Luis, Grávalos Cristina, García-Alfonso Pilar, Pachón Vanessa, Longo Federico, Martínez Virginia, Blanco Carolina, Iglesias Irene, Sanjurjo María, López-Fernández Luis |
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Pharmacogenetics and genomics 2019 Mar . Innocenti Federico, Jiang Chen, Sibley Alexander B, Denning Stefanie, Etheridge Amy S, Watson Dorothy, Niedzwiecki Donna, Hatch Ace J, Hurwitz Herbert I, Nixon Andrew B, Furukawa Yoichi, Kubo Michiaki, Crona Daniel J, Kindler Hedy L, McLeod Howard L, Ratain Mark J, Owzar Kour |
| CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2019 Mar . Liu Duo, Li Xiang, Li Xuehua, Zhang Mingyan, Zhang Juan, Hou Dan, Tong Zhiqiang, Dong M |
| Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. British journal of clinical pharmacology 2018 Dec . Cohen R, Preta L H, Joste V, Curis E, Huillard O, Jouinot A, Narjoz C, Thomas-Schoemann A, Bellesoeur A, Tiako Meyo M, Quilichini J, Desaulle D, Nicolis I, Cessot A, Vidal M, Goldwasser F, Alexandre J, Blanchet |
| Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer. The International journal of biological markers 2019 Oct 1724600819882940. Li Jing, Xu Dan, Huang Jian, Wang Yan-Na, Ma Xiao-Ping, Lin Zhi-Yi, Gong Pi |
| Analysis of clinicopathological and molecular features of crawling-type gastric adenocarcinoma. Diagnostic pathology 2020 Sep 15 (1): 111. Fujita Yasuko, Uesugi Noriyuki, Sugimoto Ryo, Eizuka Makoto, Toya Yosuke, Akasaka Risaburo, Matsumoto Takayuki, Sugai Tamot |
| Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients. Neoplasma 2021 Mar . Hu Lili, Mao Xintong, Gao Chao, Xu Yinhai, Li Chenglin, Wang Tao, Lv Dongm |
| Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer. BioMed research international 2021 10 2021 9949272. Ma Zuyi, Li Zhenchong, Ma Zuguang, Zhou Zixuan, Zhuang Hongkai, Liu Chunsheng, Huang Bowen, Zou Yiping, Zheng Zehao, Yang LinLing, Gong Yuanfeng, Huang Shanzhou, Zhou Qi, Zhang Chuanzhao, Hou Baoh |
| Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO open 2020 Dec 6 (1): 100019. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes A A, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino |
| Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. The pharmacogenomics journal 2021 Jan . Vivaldi Caterina, Crucitta Stefania, Catanese Silvia, Cucchiara Federico, Arrigoni Elena, Pecora Irene, Rofi Eleonora, Fornaro Lorenzo, Salani Francesca, Massa Valentina, Vasile Enrico, Morganti Riccardo, Danesi Romano, Del Re Marz |
| Differences in actionable genomic alterations between brain metastases and non?brain metastases in patients with non?small cell lung cancer. International journal of oncology 2022 Sep 61 (3): . Nian Rui, Jiang Huihui, Zhao Jiangman, Hou Wanle, Zhang Hua, Ma Jiangtao, Lv Pengbiao, Jiang Lisha, Wang Yongpan, Xu Yue, Wu Shouxin, Lou Jingwei, Li Wanj |
| Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia. Cancer reports (Hoboken, N.J.) 2022 11 e1744. Yunis Luz K, Linares-Ballesteros Adriana, Aponte Nelson, Barros Gisela, García Johnny, Niño Laura, Uribe Gloria, Quintero Edna, Yunis Juan |
| Genetic Variants in the Mitochondrial Thymidylate Biosynthesis Pathway Increase Colorectal Cancer Risk. Current oncology (Toronto, Ont.) 2023 9 30 (9): 8039-8053. Entesar M Arrait, Ayat B Al-Ghafari, Huda A Al Doghaith |
| Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk. Cells 2023 8 12 (15): . Aurora Gómez-Vecino, Roberto Corchado-Cobos, Adrián Blanco-Gómez, Natalia García-Sancha, Sonia Castillo-Lluva, Ana Martín-García, Marina Mendiburu-Eliçabe, Carlos Prieto, Sara Ruiz-Pinto, Guillermo Pita, Alejandro Velasco-Ruiz, Carmen Patino-Alonso, Purificación Galindo-Villardón, María Linarejos Vera-Pedrosa, José Jalife, Jian-Hua Mao, Guillermo Macías de Plasencia, Andrés Castellanos-Martín, María Del Mar Sáez-Freire, Susana Fraile-Martín, Telmo Rodrigues-Teixeira, Carmen García-Macías, Julie Milena Galvis-Jiménez, Asunción García-Sánchez, María Isidoro-García, Manuel Fuentes, María Begoña García-Cenador, Francisco Javier García-Criado, Juan Luis García-Hernández, María Ángeles Hernández-García, Juan Jesús Cruz-Hernández, César Augusto Rodríguez-Sánchez, Alejandro Martín García-Sancho, Estefanía Pérez-López, Antonio Pérez-Martínez, Federico Gutiérrez-Larraya, Antonio J Cartón, José Ángel García-Sáenz, Ana Patiño-García, Miguel Martín, Teresa Alonso-Gordoa, Christof Vulsteke, Lieselot Croes, Sigrid Hatse, Thomas Van Brussel, Diether Lambrechts, Hans Wildiers, Hang Chang, Marina Holgado-Madruga, Anna González-Neira, Pedro L Sánchez, Jesús Pérez Losa |
| Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy. Cancers 2023 3 15 (5): . Urtasun Andrea, Olivera Gladys G, Sendra Luis, Aliño Salvador F, Berlanga Pablo, Gargallo Pablo, Hervás David, Balaguer Julia, Juan-Ribelles Antonio, Andrés María Del Mar, Cañete Adela, Herrero María Jo |
| Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients. Pharmaceutics 2023 11 15 (11): . Yasmin Cura, Almudena Sánchez-Martín, Noelia Márquez-Pete, Encarnación González-Flores, Fernando Martínez-Martínez, Cristina Pérez-Ramírez, Alberto Jiménez-Moral |
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 04, 2023
- Content source: